Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 30 of 30 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02465060	Phase II	Erdafitinib Trametinib Crizotinib Sapanisertib Fexagratinib Dasatinib Osimertinib Palbociclib Capivasertib Larotrectinib Ulixertinib Nivolumab + Relatlimab Copanlisib Sunitinib Nivolumab Pertuzumab + Trastuzumab Ipatasertib Dabrafenib + Trametinib Binimetinib Adavosertib Afatinib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Taselisib	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Active, not recruiting	USA	2
NCT03131908	Phase Ib/II	GSK2636771 + Pembrolizumab	Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss	Active, not recruiting	USA	0
NCT03624543	Phase II	CFI-400945	CFI-400945 in Patients With Advanced/Metastatic Breast Cancer	Active, not recruiting	CAN	0
NCT03673787	Phase Ib/II	Atezolizumab + Ipatasertib	A Trial of Ipatasertib in Combination With Atezolizumab (IceCAP)	Active, not recruiting	GBR	0
NCT04251533	Phase III	Alpelisib + Nab-paclitaxel Nab-paclitaxel	Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss (EPIK-B3)	Active, not recruiting	USA \| TUR \| SVN \| SVK \| POL \| NOR \| ITA \| ISR \| HUN \| HRV \| GBR \| FRA \| ESP \| DEU \| CHE \| BRA \| BGR \| AUT \| AUS \| ARG	10
NCT04592237	Phase II	Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib	Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer	Active, not recruiting	USA	0
NCT00770263	Phase I	Erlotinib + Temsirolimus	Erlotinib and Temsirolimus for Solid Tumors	Completed	USA	0
NCT01458067	Phase I	GSK2636771	A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency	Completed	USA \| GBR	1
NCT01884285	Phase I	AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib	AZD8186 First Time In Patient Ascending Dose Study	Completed	USA \| GBR \| ESP \| CAN	0
NCT02215096	Phase I	Enzalutamide GSK2636771	Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer	Completed	USA \| GBR	0
NCT02549989	Phase II	LY3023414	Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer	Completed	USA	0
NCT03317119	Phase I	Trametinib + Trifluridine-tipiracil hydrochloride	Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery	Completed	USA	0
NCT03834740	Phase I	Everolimus + Ribociclib	A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection	Completed	USA	0
NCT04551521	Phase II	Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib	CRAFT: The NCT-PMO-1602 Phase II Trial	Completed	DEU	0
NCT04632992	Phase II	Ipatasertib Atezolizumab + Capecitabine Entrectinib Atezolizumab + Docetaxel Ado-trastuzumab emtansine + Atezolizumab Capecitabine + Pertuzumab/trastuzumab/hyaluronidase-zzxf Paclitaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Alectinib Inavolisib Pertuzumab/trastuzumab/hyaluronidase-zzxf Docetaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Atezolizumab + Paclitaxel Ado-trastuzumab emtansine + Tucatinib	A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC)	Completed	USA	0
NCT03065062	Phase I	Gedatolisib + Palbociclib	Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors	Recruiting	USA	0
NCT04388852	Phase I	DS-3201b + Ipilimumab	DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers	Recruiting	USA	0
NCT05691465	Phase II	lutetium Lu 177 dotatate	Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells	Recruiting	USA	0
NCT05773326	Phase I	Temsirolimus	Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG	Recruiting	USA	0
NCT05810870	Phase II	Eribulin + MEN1611 MEN1611	PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin (SABINA)	Recruiting	ESP	0
NCT06085729	Phase Ib/II	ADI-PEG 20 + Cabazitaxel + Carboplatin	Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)	Recruiting	USA	0
NCT01870726	Phase Ib/II	Buparlisib + Capmatinib	Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma	Terminated	USA \| NLD \| ESP \| DEU \| CHE	0
NCT02576444	Phase II	Adavosertib + Olaparib Olaparib Capivasertib + Olaparib Ceralasertib + Olaparib	OLAParib COmbinations (OLAPCO)	Terminated	USA	0
NCT02761694	Phase I	ARQ 751 + Paclitaxel ARQ 751 ARQ 751 + Fulvestrant	ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations	Terminated	USA	0
NCT02920450	Phase Ib/II	Carboplatin + Gedatolisib + Paclitaxel	Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)	Terminated	USA	0
NCT02961283	Phase I	ASN003	Study of ASN003 in Subjects With Advanced Solid Tumors	Terminated	USA	0
NCT02987959	Phase II	Sapanisertib	Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas	Terminated	USA	0
NCT04586270	Phase I	TAS0612	A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer	Terminated	USA \| FRA	0
NCT04737109	Phase Ib/II	Darolutamide + Ipatasertib	Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer	Terminated	USA	0
NCT06218667	Phase Ib/II	Copanlisib + Degarelix	A Study of Copanlisib in Combination With Degarelix in People With Prostate Cancer	Withdrawn		0

Showing 1 to 30 of 30 entries

Filter rows:

Profile Name	PTEN loss
Gene Variant Detail	PTEN loss (loss of function)
Relevant Treatment Approaches	Akt Inhibitor (Pan) Akt1 Inhibitor Akt2 Inhibitor PI3K Inhibitor (Pan) PIK3CB inhibitor

Molecular Profile Detail

Contact

Filtering

Sorting